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Abstract: According to the food addiction (FA) model, the consumption of certain types of food
could be potentially addictive and can lead to changes in intake regulation. We aimed to describe
metabolic parameters, dietary characteristics, and affective and neurocognitive vulnerabilities of
individuals with and without FA, and to explore its influences on weight loss progression. The
sample included 448 adults (55–75 years) with overweight/obesity and metabolic syndrome from
the PREDIMED-Plus cognition sub-study. Cognitive and psychopathological assessments, as well as
dietary, biochemical, and metabolic measurements, were assessed at baseline. Weight progression
was evaluated after a 3-year follow up. The presence of FA was associated with higher depressive
symptomatology, neurocognitive decline, low quality of life, high body mass index (BMI), and high
waist circumference, but not with metabolic comorbidities. No differences were observed in the
dietary characteristics except for the saturated and monounsaturated fatty acids consumption. After
three years, the presence of FA at baseline resulted in a significantly higher weight regain. FA is
associated with worse psychological and neurocognitive state and higher weight regain in adults
with metabolic syndrome. This condition could be an indicator of bad prognosis in the search for a
successful weight loss process.
Keywords: food addiction; metabolic syndrome; neurocognitive state; depression; quality of life
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1. Introduction
According to the food addiction (FA) model, the consumption of certain types of food
(sugary, salty, fatty, and processed) could be potentially addictive, presenting similarities
with substance use disorders (SUD) by activating brain reward systems [1]. It has been
suggested that the continuous intake of these high palatable foods can lead to changes
in the food intake regulation [2], and could explain people’s difficulty to attach to other
healthy dietary patterns [3] and overeating.
It has been found a higher prevalence of FA in individuals with obesity (18–24%) [4–7],
than in normal-weight population (2–12%) [8–12].
Even though the prevalence of FA has been widely studied, its association with the
obesity-related comorbidities remains unclear. In a sample of individuals eligible for obesity
surgery with a body mass index (BMI) of ≥35 kg/m2, FA was not associated with metabolic
comorbidities such as type 2 diabetes (T2D), hypertension, or non-alcoholic fatty liver
disease [13]. Nonetheless, there is no available information about this association among an
elder population with overweight and class 1 obesity. Evidence regarding the association
between metabolic biochemical parameters and FA is also scarce. A previous study has
shown that fasting plasma glucose levels were lower in patients with FA. However, the
levels of serum insulin, homeostasis model assessment of insulin resistance (HOMA-IR),
glycated hemoglobin (HbA1c), and the lipid serum profile were comparable in participants
with and without FA [14].
FA may also affect food choice and calorie intake. It has been previously reported that
higher FA scores were associated with higher energy intake [15], and that individuals with
FA had higher dietary fat intake compared to those without FA [1] and higher BMI [16].
Besides the influence of FA in biological processes, it has been also related with
other psychiatric disorders, such as eating disorders [4,17–21], anxiety [22], and behavioral
addictions [23], being suggested as a transdiagnostic construct that underlines different
conditions [24,25]. Particularly, higher depressive symptomatology has been found in the
population with FA [18,22,24,26], presenting a positive association between both. Addition-
ally, FA has been associated with impairments in quality of life, involving psychological,
physical, and social aspects in both clinical [27] and non-clinical populations [28,29].
FA in individuals with obesity has also been related to impaired executive functions,
such as decision making or attentional capacity [30] and cognitive impairment [31]. How-
ever, as far as we know, no study has measured the neurocognitive state related to FA in an
advanced age population with metabolic syndrome.
The aims of the present study are threefold: (i) to describe metabolic parameters
and dietary characteristics of individuals with and without FA, (ii) to describe affective
and neurocognitive underlying vulnerabilities of individuals with and without FA, and
(iii) to explore whether FA status, presence (FA+)/absence (FA−), influences weight loss
progression. After reviewing the existing evidence, we hypothesize that those individuals
with FA will present the worst metabolic state, more depressive symptomatology, and
worse neurocognitive performance, as well as showing a worse weight loss progression in
contrast with those without FA.
2. Materials and Methods
2.1. Study Design and Population
The PREDIMED-Plus (PREvención con DIeta MEDiterránea Plus) is a 6-year ongoing,
multicenter, randomized parallel-group, intervention study with the primary objective of
assessing the effects of an intensive lifestyle intervention with an energy-reduced Mediter-
ranean diet (MedDiet), physical activity promotion, and behavioral support on primary
prevention of cardiovascular disease (CVD) events. The PREDIMED-Plus study total cohort
includes 6874 participants, recruited in 23 different Spanish centers, and randomly assigned
to either an intensive weight loss intervention group, based on an energy-restricted Med-
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Diet with physical activity promotion and behavioral support, or to a control group,
advised to follow an ad libitum MedDiet without any other indication. The sample in-
cluded men aged between 55 and 75 years and women between 60 and 75 years old,
with overweight or obesity that met at least three components of metabolic syndrome
at the moment of enrolment. The cohort description in detail has been previously por-
trayed [32] and the protocol is available in http://predimedplus.com/ (accessed on 13
August 2021). The trial was registered in 2014 at the International Standard Randomized
Controlled Trial (ISRCT) with number ISRCT89898870. According to the ethical standards
of the Declaration of Helsinki by the Research Ethics Committees, all the participating
institutions approved the study protocol and procedures (PR240/13; H1509263926814;
2013/5276/I; 13-07-25/7proj2). All participants provided written informed consent. The
current analysis was performed in a subsample of the original population, including n =
448 individuals from the PREDIMED-Plus cognition subprogram recruited in four different
centers: Universitat Rovira i Virgili (Tarragona, Spain), Universidad de Valencia (Valencia,
Spain), Institut Hospital del Mar d’Investigacions Mèdiques-IMIM (Barcelona, Spain), and
Bellvitge University Hospital-IDIBELL (Barcelona, Spain).
2.2. Dietary Assessment
Dietary information was collected by trained dietitians at baseline and yearly thereafter
during the follow-up visits. Total energy, macro, and micronutrients intake were assessed
by a semi-quantitative 143-item food frequency questionnaire (FFQ) and estimated using
Spanish food composition tables [33,34].
2.3. Biochemical, Anthropometric and Blood Pressure Measurements
Trained personnel assessed duplicated weight, height, and waist circumference at
baseline, and subsequently at each of the follow-up visits. Body mass index (BMI, kg/m2)
was later calculated using this information. Fasting blood samples were collected in order
to perform biochemical analyses. Biochemical measurements included fasting plasma
glucose, HbAc1 and insulin, albumin, transaminase enzymes, and lipid profile (total
cholesterol, HDL-c, LDL-c and triglycerides). Blood pressure was measured 3 times using a
validated semiautomatic oscillometer (Omron HEM-705CP). HOMA-IR was estimated with
the formula: fasting glucose levels [mg/dL] × fasting insulin levels [µU/mL]/405,13 [35].
2.4. Psychometric Measures
Psychometric assessment was conducted by self-report questionnaires.
Yale Food Addiction Scale (YFAS) [3] has been validated in Spanish population [5]. It
is a 25-item self-report questionnaire for measuring addictive eating behaviors, based on
the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR) [36] criteria for
substance dependence, adapted to the context of food consumption. Two scoring options
are used to indicate the experience of addictive eating behavior: a dimensional (Likert
scale) and a binary score. FA is diagnosed when at least three symptoms and a clinically
significant impairment or distress are present within the previous 12 months. The internal
consistency of the YFAS in our sample was α = 0.914.
The Beck Depression Inventory–II (BDI-II) [37] has been validated in Spanish general
population [38]. It is a self-report questionnaire of 21 items that assess the severity of
depressive symptoms in adults and adolescents, reflecting the diagnostic criteria for major
depressive disorder listed in the DSM-5 [39]. Scores for each item range from 0 to 3,
being the total score the sum of all responses. The standardized cut-offs are follows: 0–13
indicates minimal depression, 14–19 mild depression, 20–28 moderate depression, 29–63
severe depression. The internal consistency of the BDI-II in our sample was α = 0.873.
Short Form-36 Health Survey (SF-36) [40] has been validated in Spanish popula-
tion [41]. It is a self-report questionnaire of 36 items in its short form. It is a generic measure
of health status, through eight subscales: physical functioning, physical role, bodily pain,
general health, vitality, social functioning, emotional role, and mental health. The higher
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the score, the better general quality of life. The internal consistency of the SF-36 in our
sample was α = 0.933.
2.5. Cognitive Assessment
Montreal Cognitive Assessment (MoCA) [42] is a neurocognitive screening tool to
detect mild cognitive impairment. It takes 7 to 10 min to be administered by healthcare
professionals. The test assesses multiple cognitive functions, including short-term memory,
visuospatial abilities, executive functioning, phonemic fluency, attention, concentration,
working memory, language, and orientation. The test score ranges from 0 to 30, with
higher scores indicating better performance. If the years of education are below 12, one
point should be added to the final score. The test has been validated previously in Spanish
population [43].
2.6. Statistical Analysis
Statistical analysis was carried with Stata17 for Windows [44]. For this analysis, we
used the PREDIMED-Plus sub-cognition study database of January 14th, 2021.
Comparison between the groups were done with the chi-squared test (χ2) categorical
variables and the T-test for independent groups for quantitative variables. Effect size was
measured with the standardized Cohen’s d coefficient for mean differences and Cohen’s
h for proportion differences (effect size was considered null for |d| < 0.20 or |h| < 0.20,
low-poor |d| > 0.20 or |h| > 0.20, moderate–medium for |d| > 0.50 or |h| > 0.50,
and large–high for |d| > 0.80 or |h| > 0.80) [45,46] In addition, Finner’s method was
used to control the increase in the Type-I error due to the application of multiple null-
hypothesis significance tests (this is a stepwise multiple test procedure aimed to adjust
p-values controlling the familywise error rate, FWER) [47]. Missing data was handled by
a multiple imputation (MI) procedure implemented in Stata17, which provides unbiased
estimate parameters and their respective standard errors using Rubin’s combination rules
and making no assumption about the missing-data mechanism [48,49].
The evolution of the BMI during the study was analyzed with 2×4 mixed analysis of
variance (ANOVA), defining the group as the between-subjects factor (FA− versus FA+)
and the time as the within-subjects factor (baseline, 1-yr, 2-yr, and 3-yr of the follow-up).
3. Results
3.1. Descriptive for the Sample
Table 1 displays the distribution for the total sample and the comparison for the
patients with FA− and FA+. Among the total sample, the distribution of sex was 217
men (48.4%) versus 231 women (51.6%). Most participants were born in Europe (98.2%),
were married, or lived with a stable partner (78.3%), achieved primary education levels
(53.6%), and were retired (64.3%). Regarding the group of weight, the greatest likelihood
was being in the obesity-I level (48.7%). Regarding comparison between the groups with
the FA negative versus positive screening scores, differences only were found for the group
of weight: FA+ associated with higher obesity levels.
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(n = 422) FA Positive (n = 26)
n % n % n % χ2 df p
Sex Male 217 48.4% 208 49.3% 9 34.6% 2.11 1 0.146
Female 231 51.6% 214 50.7% 17 65.4%
Origin Europe 440 98.2% 415 98.3% 25 96.2% 0.67 1 0.414
South
America 8 1.8% 7 1.7% 1 3.8%
Civil status Single 17 3.8% 16 3.8% 1 3.8% 4.14 3 0.247
Married 351 78.3% 333 78.9% 18 69.2%
Divorced-
separated 30 6.7% 29 6.9% 1 3.8%
Widowed 50 11.2% 44 10.4% 6 23.1%
School University(high) 42 9.4% 38 9.0% 4 15.4% 1.39 3 0.708
University
(grade) 37 8.3% 35 8.3% 2 7.7%
Secondary 129 28.8% 123 29.1% 6 23.1%
Primary 240 53.6% 226 53.6% 14 53.8%
Employment Unemployed 80 17.9% 76 18.0% 4 15.4% 1.48 4 0.831
Work at
home 46 10.3% 43 10.2% 3 11.5%








13 2.9% 13 3.1% 0 0.0%












4 0.9% 4 0.9% 0 0.0%
Mean SD Mean SD Mean SD F df p
Age, years-old 65.25 4.63 65.22 4.63 65.73 4.64 0.30 1.446 0.582
Note. SD: standard deviation. df: degrees of freedom. * Bold: significant comparison.
3.2. Comparison of Metabolic and Dietary Measures
Table 2 contains the results of the comparison between the groups for metabolic and
dietary measures. The patients within the FA+ condition reported a higher mean for weight,
BMI, and waist circumference. No differences were observed in the lipid profile, in the
parameters of glucose metabolism, liver function, blood pressure values. and physical
activity total energy expenditure. Regarding dietary information, participants with FA had
a higher intake of monounsaturated fatty acids (MUFAs) (grams and percentage estimates),
saturated fatty acids (SFAs) (grams and percentage estimates), and grams per day of trans
fatty acids.
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Table 2. Comparison of metabolic and dietary measures.
FA Negative (n = 422) FA Positive (n = 26)
Mean SD Mean SD p |d|
Total cholesterol,
mg/dL 207.70 40.10 215.00 36.63 0.366 0.19
Triglycerides,
mg/dL 160.81 77.69 155.08 81.02 0.716 0.07
LDL cholesterol,
mg/dL 125.65 33.69 128.58 32.47 0.666 0.09
HDL cholesterol,
mg/dL 51.11 12.95 55.46 10.02 0.093 0.38
Albumin, g/dL 4.43 0.50 4.52 0.24 0.401 0.21
Glucose, mg/dL 116.81 30.18 110.81 18.53 0.317 0.24
Insulin, mIU/ml 18.68 8.64 18.36 8.37 0.855 0.04
HOMA-IR 5.45 3.08 5.13 2.66 0.607 0.11








24.12 8.45 22.85 6.81 0.454 0.17
Systolic blood
pressure, mm Hg 140.75 15.03 139.69 13.21 0.725 0.07
Diastolic blood





849.05 801.20 769.23 832.43 0.623 0.10
Weight, kg 85.42 13.39 91.29 14.50 0.031 * 0.42
BMI, kg/m2 32.38 3.39 35.06 3.07 <0.001 * 0.83 †
Waist circumference,
cm 107.53 10.15 111.88 11.02 0.035 * 0.41
Total energy intake,
kcal/day 2398.66 573.70 2527.12 815.43 0.282 0.18
Carbohydrate, g/d 241.40 78.35 245.12 92.33 0.816 0.04
Carbohydrate, % 39.93 6.53 38.48 7.04 0.276 0.21
Protein, g/d 100.57 20.83 104.97 26.46 0.304 0.19
Protein, % 17.10 2.90 17.20 2.87 0.869 0.03
Total fat, g/d 107.66 28.71 119.47 46.04 0.052 0.31
Total fat, % 40.52 6.12 42.55 5.66 0.099 0.35
SFAs, g 27.69 9.21 31.65 12.89 0.039 * 0.35
SFAs, % 10.33 1.92 11.15 1.99 0.034 * 0.42
MUFAs, g/d 55.28 14.98 63.53 25.87 0.010 * 0.39
MUFAs, % 20.91 4.20 22.70 3.75 0.035 * 0.45
PUFAs, g/d 18.12 6.58 19.58 8.19 0.280 0.20
PUFAs, % 6.80 1.80 6.93 1.41 0.710 0.08
Trans fatty acids,
g/d 0.65 0.41 0.87 0.50 0.009 * 0.48
Prevalence n % n % p |h|
Hypertension 317 75.1% 23 88.5% 0.123 0.35
Diabetes 121 28.7% 6 23.1% 0.539 0.13
Hypercholesterolemia 216 51.2% 13 50.0% 0.907 0.02
Note. SD: standard deviation, MET, metabolic equivalent of task, SFA: saturated fatty acids, MUFA: monounsatu-
rated fatty acids, PUFA: polyunsaturated fatty acids. * Bold: significant comparison. † Bold: effect size into the
range mild–moderate to high–large.
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3.3. Comparison of Psychological and Neuropsychological Measures
Table 3 contains the results of the comparison between the groups for the BDI, SF-36,
and the MoCa scores. The presence of FA+ was associated with worse psychological state,
except for the SF-36 physical pain domain.
Table 3. Comparison of psychological measures.
FA Negative (n = 422) FA Positive (n = 26)
Mean SD Mean SD p |d|
BDI total score 7.97 6.42 14.92 9.38 <0.001 * 0.87 †
SF-36 total score 78.34 16.35 63.46 18.33 <0.001 * 0.86 †
SF-36 physical
function 75.84 18.98 63.27 18.05 0.001 * 0.68
†
SF-36 physical role 77.86 33.33 48.08 41.79 <0.001 * 0.79 †
SF-36 physical pain 70.43 22.54 62.31 21.41 0.075 0.37
SF-36 general health 76.21 16.78 66.92 17.27 0.007 * 0.55 †
SF-36 vitality 62.73 20.28 46.15 22.06 <0.001 * 0.78 †
SF-36 social function 92.48 14.29 84.73 19.11 0.009 * 0.46
SF-36 emotional role 87.92 28.19 67.96 42.69 0.001 * 0.55 †
SF-36 mental health 75.10 18.83 64.31 17.89 0.005 * 0.59 †
MoCA total 23.58 4.31 21.42 6.54 0.017 * 0.39
* Bold: significant comparison. † Bold: effect size into the range mild–moderate to high–large.
3.4. Evolution of the BMI during the Study
Figure 1 shows the line graph with the means registered for the BMI at the beginning
of the study and during the three years of the follow-up. Table S1 (Supplementary Material)
contains the complete results of the 2×3 ANOVA. A significant interaction group-by-time
was found (F (df = 2.431) = 4.18, p = 0.021, η2 = 0.010), suggesting that the progression
of the BMI during the study was different in each FA condition. Concretely, polynomial
contrasts evidenced a quadratic trend within the FA− condition (p = 0.004, η2 = 0.020),
while no linear-quartic trend emerged within the FA+ condition. Contrasts for the factor
group (FA+ versus FA− comparisons) also achieved significant results, with higher mean
scores among patients with FA+ at baseline (p = 0.001, η2 = 0.034) and at three years of the
follow-up (p = 0.001, η2 = 0.033).
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without food addiction, and to explore whether FA status (presence/absence) influences
weight loss progression, in a metabolic syndrome at high cardiovascular risk population.
The prevalence of FA in our sample reached 5.8%, underneath the number of the
general population that has been reported to be about 8% [50]. However, information of
the prevalence of FA among the elderly population is scarce. Data from the Nurses’ Health
Studies (NHS) cohort, a sample of women aged between 60 and 88 years old, showed that
the number of cases of FA reached 2.7%. This prevalence was strongly linked with age,
reaching 6% in the age range of 60–65 years, and continually decreased till 1.4% in ages
between 75 and 88 [51]. The decline in the prevalence of FA diagnosis while increasing in
age could be associated with several physiological alterations related to the ageing process,
including changes in the taste and smell senses [52] that could be affecting the motivation
for palatable food, as well as changes in the physiology of several endocrinal factors such
as ghrelin, cholecystokinin, and leptin that may result in a relevant decrease in appetite
and food intake [53].
As our first aim, we explored the metabolic status and the presence of comorbidities.
In our study, the diagnosis of FA was associated with higher total weight, BMI, and
higher rates of morbid obesity (BMI ≥ 35 kg/m2). Previous findings have reported similar
associations [51,54,55]. Yet, in our study, no link was observed between the presence of
FA and obesity-related comorbidities. This lack of association may be due to the general
characteristics of the study population, individuals with overweight or obesity that met at
least three components of metabolic syndrome at the moment of enrolment, and therefore
at high cardiovascular risk. Nonetheless, we did observe a significant difference in the
waist circumference values, an indicator of abdominal obesity and a predictor of metabolic
disorders such as T2D and CVD [56].
It is worth mentioning that, even though the presence of FA could be considered
a contributor factor in the weight gain and latter development of obesity, the fat mass
accumulation and the obesity-related comorbidities are affected by several other influences,
such as the dietary pattern, the metabolic state, genetics, and epigenetics, among others [57].
Regarding the dietary characteristics of our sample, we were not able to identify any
differences in-between the macronutrient dietary profile and the total calorie intake of the
FA and non-FA participant groups. Nevertheless, we did observe significant differences in
the fatty acid distribution, specifically in the saturated and monounsaturated fatty acid
consumption, as well as in the trans fatty acid intake. The same differences were described
in previous findings, where individuals with obesity and FA exhibited a significantly higher
consumption of fat subcomponents: saturated, monosaturated, polyunsaturated, and trans
fats [58]. Food with a high content of fat, especially saturated and trans fatty acids, are
highly palatable and more likely to be excessively consumed and to be associated with
compulsive overeating [59].
In relation to our second aim, higher depressive symptomatology was found in those
patients presenting FA. The presence of depression among metabolic syndrome patients
have already been mentioned in the literature [60–63], as well as the association between FA
and depression [18,22,24,26]. A possible common feature between both comorbidities could
be the use of the eating behavior as a way to regulate negative emotional states that may
lead to overeating [64], as well as to changes in the food intake regulation [2], establishing a
continuous feedback between each other [10]. Depression has been associated with higher
daily caloric intake [64], and high adipose mass has been associated with several metabolic
disturbances that are implicated in the control of emotions and mood [65,66]. This may
explain the increase of depression in our sample, from minimal depression in those without
FA, to mild depression in those with FA, according to the standardized cut-offs [37].
In a similar way, according to what it was hypothesized, those patients with FA
presented higher impairments in all the assessed parameters of quality of life than those
without FA, except for the one related to physical pain. Impairments in quality of life have
been already mentioned in the literature in populations that present FA [27–29], but just a
few studies have explored the influence of FA over the quality of life in contrast with the
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other metabolic parameters. Its findings are in concordance with the ones of the present
study, being that the metabolic disturbances seem not to be enough to imply detriments in
quality of life [14], but the presence of FA does. As has been mentioned in the literature,
addictive processes, both behavior- and substance use-related, decreases quality of life [67].
Regarding the neurocognitive assessment, our results showed that FA+ group pre-
sented lower scores in a general cognitive state test than the group without FA, pointing out
that FA was related to a more pronounced cognitive decline in an older adult population
with metabolic syndrome. Fast food intake in elderly population has been already associ-
ated with higher incidence of mild cognitive impairment [68], as well as the preference for
processed foods with poorer cognitive performance and impaired executive functioning
in this population [69]. In contrast, higher adherence to the Mediterranean diet has been
associated with a reduced risk for developing mild cognitive impairment in nondemented
elderly participants [70]. Our results may suggest that the presence of FA patterns could be
associated with an increased risk of cognitive decline within this population.
Finally, one of the most relevant contributions of this study is the longitudinal assess-
ment of the effect of FA on the evolution of weight at three years. Our results indicate
that the presence of FA at baseline resulted in a significant higher weight regain after
three years, when following a Mediterranean diet. These findings are consistent with
prior research that observed an association between the presence of FA and worse results
while seeking a weight loss [71–73]. Previous results from our group showed that among
individuals with obesity seeking bariatric surgery, the presence of FA at baseline predicted
poorer weight loss achievement after a dietary and lifestyle intervention before the surgical
intervention [6].
These findings may suggest that the presence of FA could be an indicator of bad
prognosis on the search for a successful weight loss process, influencing the final outcome
in the treatments. Nonetheless, there is also evidence that the FA symptoms can diminish
after a weight reduction [74,75]. Therefore, taking all this into account, even though the
presence of FA could be considered a disadvantage at the moment of reaching a successful
result, implementing additional and specialized support to these individuals during the
treatment may be a good strategy for obtaining better results [25].
Limits and Strengths
Our study has some limitations that should be considered. The study cohort, a
Mediterranean older adult population with metabolic syndrome at high cardiovascular
risk, is not representative of the general population, and therefore our results cannot be
extrapolated. As in any observational study, the possibility of residual or unmeasured
confounding could not be eliminated. Additionally, even though FFQs are suitable tools
for epidemiological studies’ dietary assessment, being a subjective method, we cannot
disregard some errors in the estimation of the dietary information.
Despite its limitations, this study adds a characterization of a population that has not
been previously thoroughly described, a senior population with food addiction symptomatology.
5. Conclusions
As general a conclusion, the results of this study indicated that the presence of FA is
associated with higher depressive symptomatology, worse neurocognitive state, and lower
quality of life than with metabolic parameters. Additionally, those participants with FA had
higher weight regain than those without FA after three years of follow-up. All these factors
may be indicators of worse prognosis for metabolic syndrome patients that also present
FA, for which the present results may be helpful in order to establish better treatment
approaches. It is possible to suggest that the population with FA could benefit from both a
diet-based treatment as well as a specific one targeting the addictive process, which could
improve the psychological, social, and neurological functioning of the patients.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/10
.3390/nu13082779/s1, Table S1: Evolution of BMI (kg/m2) during the study: Mixed 2 × 3 ANOVA.
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